Loading...

Tong Ren Tang Technologies Co. Ltd.

TGRNFPNK
Healthcare
Drug Manufacturers - General
$0.62
$0.00(0.00%)

Tong Ren Tang Technologies Co. Ltd. (TGRNF) Financial Performance & Income Statement Overview

Review Tong Ren Tang Technologies Co. Ltd. (TGRNF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
7.18%
7.18%
Operating Income Growth
-11.74%
11.74%
Net Income Growth
-11.59%
11.59%
Operating Cash Flow Growth
-97.18%
97.18%
Operating Margin
16.11%
16.11%
Gross Margin
40.97%
40.97%
Net Profit Margin
9.46%
9.46%
ROE
9.10%
9.10%
ROIC
9.58%
9.58%

Tong Ren Tang Technologies Co. Ltd. (TGRNF) Income Statement & Financial Overview

Analyze Tong Ren Tang Technologies Co. Ltd.’s TGRNF earnings with segmented quarterly and yearly financial statement figures.

MetricQ4 2024Q2 2024Q4 2023Q2 2023
Revenue$3.21B$4.05B$2.83B$3.95B
Cost of Revenue$1.87B$2.51B$1.55B$2.38B
Gross Profit$1.34B$1.54B$1.28B$1.57B
Gross Profit Ratio$0.42$0.38$0.45$0.40
R&D Expenses$32.17M$52.65M$47.79M$69.77M
SG&A Expenses$987.67M$905.09M$804.99M$926.51M
Operating Expenses$987.25M$905.08M$805.01M$921.53M
Total Costs & Expenses$2.86B$3.42B$2.35B$3.30B
Interest Income$0.00$0.00$27.28M$14.58M
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$91.18M$94.93M$93.50M$92.61M
EBITDA$444.30M$726.98M$569.08M$733.24M
EBITDA Ratio$0.14$0.18$0.20$0.19
Operating Income$353.12M$632.04M$475.58M$640.63M
Operating Income Ratio$0.11$0.16$0.17$0.16
Other Income/Expenses (Net)$17.56M$58.49M$26.86M$19.38M
Income Before Tax$370.68M$690.53M$502.44M$660.01M
Income Before Tax Ratio$0.12$0.17$0.18$0.17
Income Tax Expense$66.53M$107.75M$70.13M$100.02M
Net Income$93.04M$428.75M$222.04M$368.15M
Net Income Ratio$0.03$0.11$0.08$0.09
EPS$0.07$0.33$0.17$0.29
Diluted EPS$0.07$0.33$0.17$0.29
Weighted Avg Shares Outstanding$1.28B$1.28B$1.28B$1.28B
Weighted Avg Shares Outstanding (Diluted)$1.28B$1.28B$1.28B$1.28B

Over the last four quarters, Tong Ren Tang Technologies Co. Ltd.'s revenue moved from $3.95B in Q2 2023 to $3.21B in Q4 2024. Operating income in Q4 2024 was $353.12M, with a strong operating margin of 11%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Tong Ren Tang Technologies Co. Ltd. remained robust at $444.30M, reflecting operational efficiency. Net income dropped to $93.04M, with an EPS of $0.07. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;